Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5XN
|
|||
| Former ID |
DIB005041
|
|||
| Drug Name |
LEURUBICIN
|
|||
| Synonyms |
Doxogenix L; CT-012002; L-ADR; LEU-DOX; RP-39937; Leurubicin; N-L-Leucyladriamycin; N-L-Leucyldoxorubicin; E-88/032 (hydrochloride); (8S,10S)-10-[[3-[(S)-2-Amino-4-methylvaleramido]-2,3,6-trideoxy-alphal-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; (8S-cis)-6,8,11-Trihydroxy-8-(hydroxyacetyl)-10-[2,3,6-trideoxy-3-(L-leucylamino)-alpha-L-lyxohexopyranosyloxy]-1-methoxy-5,8,9,10,12-hexahydronaphthacene-5,12-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H40N2O12
|
|||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)C(CC(C)C)N)O
|
|||
| InChI |
1S/C33H40N2O12/c1-13(2)8-17(34)32(43)35-18-9-22(46-14(3)27(18)38)47-20-11-33(44,21(37)12-36)10-16-24(20)31(42)26-25(29(16)40)28(39)15-6-5-7-19(45-4)23(15)30(26)41/h5-7,13-14,17-18,20,22,27,36,38,40,42,44H,8-12,34H2,1-4H3,(H,35,43)/t14-,17-,18-,20-,22-,27+,33-/m0/s1
|
|||
| InChIKey |
HROXIDVVXKDCBD-ZUWKMVCBSA-N
|
|||
| CAS Number |
CAS 70774-25-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001292) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.